§ Claim under review · Mixed
"Scientists have created a chewing gum made from the lablab bean plant that kills/reduces viruses in the mouth, including SARS-CoV-2, herpes, and influenza"
Verdict
Source exists but framing is misleading
Confidence
HighSummary
The study behind this is real. Researchers at the University of Pennsylvania, with collaborators in Finland, published a peer-reviewed paper in Molecular Therapy in January 2025 describing an experimental chewing gum made from lablab bean powder. The bean naturally contains a protein called FRIL that grabs onto sugar structures found on the surface of many viruses. In laboratory tests, the gum reduced measurable levels of two influenza A strains and both herpes simplex viruses by roughly 90 to 95 percent, and earlier work showed activity against SARS-CoV-2. Two important caveats: the protein traps and clumps viruses rather than killing them, and all of this was done in test tubes and in a mechanical chewing machine using artificial saliva, not in the mouths of real people. Also, the frequently quoted 95 percent figure for COVID came from a related but different gum made from engineered lettuce, and the planned human trial for that product is listed on the government registry as withdrawn and never opened. So the technology is promising and legitimately published, but it has not been shown to prevent or treat flu, COVID, or herpes in actual use.
The readings
key figures from the evidencestatus of Penn ACE2 chewing gum clinical trial NCT05433181
Why this verdict
Evidence
The underlying research is real, published in a peer-reviewed journal, and matches the general shape of the claim. Henry Daniell and collaborators tested the ability of a chewing gum made from lablab beans, Lablab purpureus, which naturally contain an antiviral trap protein (FRIL), to neutralize two herpes simplex viruses (HSV-1 and HSV-2) and two influenza A strains (H1N1 and H3N2).
They demonstrated that 40 milligrams of a two-gram bean gum tablet was adequate to reduce viral loads by more than 95%, a reduction similar to what they saw in their SARS-CoV-2 study.
The mechanism is physical trapping rather than killing. Bean gum extracts trapped HSV-1/HSV-2 75 to 94% in a dose-dependent manner through virus self-aggregation.
Purified FRIL protein at greater than 10 micrograms per milliliter neutralized more than 90% of influenza H1N1 and 95% of H3N2, while the bean gum required 40.77 milligrams per milliliter containing 36 to 38 micrograms per milliliter of FRIL to achieve similar neutralization . Bean gum also neutralized more than 95% of HSV-1 at 148 micrograms per milliliter of FRIL, compared with 68.52 micrograms per milliliter of FRIL against HSV-2.
For SARS-CoV-2, the strongest results came from an earlier, related but different gum. In omicron nasopharyngeal samples, microbubble counts were significantly reduced by 20 micrograms of FRIL and by 0.925 micrograms of CTB-ACE2, and among 20 delta or omicron nasopharyngeal samples, 17 had viral load reduced below the detection level of spike protein after incubation with the CTB-ACE2 gum powder.
A dose-dependent 50% plaque reduction against influenza H1N1, H3N2, and coronavirus HCoV-OC43 was observed with purified FRIL, lablab bean powder, or gum. The widely quoted "more than 95% against SARS-CoV-2" figure attaches to the CTB-ACE2 gum, which is made from lettuce engineered to produce ACE2, not from lablab beans: CTB-ACE2 chewing gum was able to markedly debulk SARS-CoV-2 (greater than 95%) in COVID-19 patient saliva or swab samples, consistent across beta, delta, and omicron variants.
Findings
✓ What's accurate 6
- Scientists did develop an experimental chewing gum made from lablab bean powder. This is documented in a peer-reviewed Molecular Therapy paper.
- The bean contains a naturally occurring protein, FRIL, that binds viral particles. FRIL binds to complex-type N-glycans, which are found on a broader spectrum of viruses, including SARS-CoV-2 and influenza viruses , which is why the effect is not virus-specific.
- Influenza A (H1N1, H3N2) and both herpes simplex viruses (HSV-1, HSV-2) were directly tested with the bean gum, with reductions above 90 to 95% at achievable concentrations.
- Lablab bean powder and FRIL also showed activity against SARS-CoV-2 and a seasonal coronavirus in the earlier 2022 work.
- The gum was manufactured to clinical-grade standards and showed long shelf stability and reliable protein release in a chewing simulator.
- The research team includes an academic collaboration across Penn, the Natural Resources Institute Finland, and the University of Helsinki, and the paper is open access.
≈ What's misleading 6
- Exaggeration and mechanism error: "kills viruses" is wrong. The described mechanism is binding and clumping viral particles so they aggregate and are neutralized or removed, not killing them. The paper describes trapping through virus self-aggregation.
- Setting mismatch: "reduces viruses in the mouth" implies demonstrated effect in human mouths. The evidence is in vitro and in a mechanical chewing simulator with artificial saliva. No human chewed the gum and had viral load measured.
- Virus substitution: the headline groups SARS-CoV-2 with the flu and herpes results as if all came from the lablab bean gum. The most cited SARS-CoV-2 figure of greater than 95% came from the CTB-ACE2 lettuce-based gum, a related but different product from the same lab.
- Temporal and status overreach in the press cycle: institutional and media coverage described the approach as already in clinical trial, while the registry shows the trial was withdrawn and never opened. Readers would reasonably infer human testing was underway.
- Omitted qualifier on herpes: the herpes result is a laboratory virus-neutralization result. It says nothing about preventing outbreaks, treating cold sores, or reducing transmission between people.
- Dose framing: the "40 milligrams of a two-gram tablet is enough" line is a concentration comparison against virus levels typical of saliva in a dish, not a demonstration of dosing sufficiency in a real mouth over time.
? What's uncertain 4
- Whether any human clinical trial of the lablab bean gum has been registered or opened since early 2025. Search capacity was exhausted before this could be confirmed.
- Whether reducing oral viral load actually reduces transmission or infection in people. This is the stated hypothesis of the research program, not a demonstrated outcome.
- Real-world duration of effect, safety with repeated use, and whether allergenicity of a bean-derived protein poses issues at scale.
- Whether HSV reductions in a dish translate to any clinical benefit given that HSV establishes latency in nerve tissue, which a gum cannot reach.
Sources
5 of 6 linked to recordsDaniell H, Guo Y, Singh R, Karki U, Kulchar RJ, Wakade G, Pihlava JM, Khazaei H, Cohen GH. "Debulking influenza and herpes simplex virus strains by a wide-spectrum anti-viral protein formulated in clinical grade chewing gum." Molecular Therapy, Vol 33, No 1, January 2025 (online Dec 2024)
Daniell H et al. "Debulking different Corona (SARS-CoV-2 delta, omicron, OC43) and Influenza (H1N1, H3N2) virus strains by plant viral trap proteins in chewing gums." Biomaterials, 2022
ClinicalTrials.gov record NCT05433181, "ACE2 Chewing Gum on SARS-CoV-2 Viral Load"
Penn Today institutional press release, April 2025
Penn Dental Medicine release on the FRIL gum development, Sept 2022
Coverage in ScienceAlert, IFLScience, New Atlas, Inside Precision Medicine, SciTechDaily, ScienceDaily, StudyFinds